Efficacy and safety of desogestrel/ethinylestradiol 150/20 flexible extended regimen (FREEDOM 150/20) in dysmenorrhea: phase 3 study in Japan Authors: Kaori Koga, Daniela Colaci, Madeline Grigg, Daisuke Goto, Tinghui Yu, Mikio Momoeda Published: 2026 ABSTRACT ObjectiveTo evaluate the efficacy and long-term safety of a user-driven flexible extended regimen of desogestrel 150 μg/ethinylestradiol 20 μg (DSG/EE 150/20) for the treatment of primary or secondary dysmenorrhea in women from Japan.DesignPhase 3, randomized, placebo-controlled, parallel-group, double-blind study with an open-label extension period.SubjectsTwo hundred and eleven women with regular menstrual cycles and primary or secondary dysmenorrhea in 21 centres across Japan.InterventionParticipants were randomly assigned (3:1) to receive DSG/EE 150/20 μg or placebo once daily for 24–80 consecutive days, with each treatment period followed by a 4-day tablet-free interval. After the double-blind phase (three 28-day cycles), participants entered an open-label phase (≤10 cycles); participants initially receiving placebo were switched to DSG/EE.Main Outcome MeasuresPrimary endpoint was change from baseline through day 84 in total dysmenorrhea score (TDS). Secondary endpoints included number of days with dysmenorrheic pain, patient global impression of change (PGI-C), treatment satisfaction questionnaire for medication (TSQM-9), quality of life (QoL) measured by the 36-item short form health survey version 2.0 (SF-36v2), and safety outcomes.ResultsIn the 211 participants randomized to DSG/EE (n = 159) and placebo (n = 52), the mean (SD) age was 32.3 (7.56) years, and body mass index was 21.94 (3.18). A significant reduction in TDS from baseline through day 84 was observed in the DSG/EE group vs. placebo (least squares mean: −2.50 vs. −0.84; treatment difference [95% confidence interval: −1.67 [−2.08, −1.26]). The number of days with mild, moderate, and severe pain were 12.9 vs. 12.1, 4.8 vs. 6.5, and 0.8 vs. 1.1 days in the DSG/EE vs. placebo group. Over 80% of DSG/EE-treated participants reported improvement in PGI-C scores compared with <30% on placebo. TSQM-9 global satisfaction and effectiveness least squares mean scores were higher with DSG/EE (63.69 vs. 36.62 and 62.86 vs. 35.5) compared with placebo. DSG/EE improved SF-36v2 scores, particularly in the physical component summary, bodily pain, and role-physical domains. Overall, the most frequent treatment-emergent adverse events were intermenstrual bleeding, nasopharyngitis, and nausea. No deaths were reported during the entire study period.ConclusionDSG/EE 150/20 effectively reduced dysmenorrhea severity, improved SF-36v2 scores and treatment satisfaction, offered dosing flexibility, and was well-tolerated with a safety profile consistent with combined oral contraceptives.Trial RegistrationjRCT2031230276 (https://jrct.mhlw.go.jp/en-latest-detail/jRCT2031230276) Dysmenorrhea is a condition that occurs during menstruation, characterized mainly by lower abdominal and back pain, and may be associated with bloating, nausea, headache, fatigue, loss of appetite, irritability, diarrhea, and depressive symptoms (1). Primary dysmenorrhea is not associated with pelvic pathology and secondary dysmenorrhea results from underlying conditions (2). The global prevalence of dysmenorrhea varies widely (3) and a recent Japanese study reported approximately 66% of women experiencing menstrual pain (4). Dysmenorrhea significantly impairs both quality of life (QoL) and work productivity (5). Low-dose estrogen-progestins (LEPs) are one of the first-line treatments for dysmenorrhea, recommended by the Japan Society of Obstetrics and Gynecology (JSOG) and the Japan Association of Obstetricians and Gynecologists (6). Flexible extended dosing of LEPs reduces the number of days with dysmenorrheic pain, withdrawal bleeding frequency, improves patient satisfaction, and QoL, by allowing scheduled hormone-free intervals (7, 8). The JSOG guidelines support menstrual cycle adjustment with oral contraceptives (OCs) to accommodate patient needs (6, 9). Although multiple LEP regimens provide various degrees of flexibility, a fully user-driven regimen is not introduced in Japan. The current LEP regimens approved in Japan (10) require a tablet-free interval (TFI) after three consecutive days of bleeding (11) or 77-day consecutive dosing (12). Therefore, a formulation with full user-driven flexibility offers a new avenue to optimize therapeutic management. We investigated the efficacy and long-term safety of an LEP formulation, desogestrel 150 μg/ethinylestradiol 20 μg (DSG/EE 150/20), in women from Japan using a user-driven flexible extended regimen (FREEDOM 150/20) for the treatment of primary or secondary dysmenorrhea. Further, this regimen allows patients to select cyclical and continuous regimens (up to 80 days) as well. Materials and methods Study design This randomized, double-blind, placebo-controlled, multicenter, parallel-group, phase 3 study was conducted at 21 centers across Japan (July 2023–April 2025). The study consisted of a before treatment screening phase conducted during the baseline cycle; a treatment phase including a randomized efficacy (double-blind) period (≤3 conventional 28-day cycles), followed by an open-label treatment extension period (OLTP) of ≤10 conventional 28-day cycles; and a 4-week post-treatment follow-up phase (Supplemental Fig. 1, available online). Additionally, active treatment period (ATP) was the period of treatment with DSG/EE. The DSG/EE group received active treatment for 12 months (double-blind treatment period [DBTP]: 3 months and OLTP: 9 months), and the placebo-DSG/EE group received active treatment for 9 months (in the OLTP only). The study was approved by a local institutional review board and conducted in accordance with the Declaration of Helsinki, International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use Good Clinical Practice (ICH-GCP) guidelines, applicable laws, and regulations. Written informed consents were obtained from all participants before inclusion in the study. Participants Women aged ≥16 years with regular menstrual cycles (28 ± 7 days) and moderate-to-severe primary or secondary dysmenorrhea diagnosis were included. Participants were included if they had dysmenorrhea during screening as defined by a mean total dysmenorrhea score (13) (TDS; Supplementary material, available online) of ≥3 after completion of the baseline cycle. The mean was calculated from the TDSs of first and last before treatment menstruation cycles. Participants were required to have no contraindications to progestin/EE combination and agreed to use contraception during the study. Key exclusion criteria included participants with a history of sex steroid-influenced malignancies, undiagnosed genital bleeding, clinically significant gynecologic conditions (complex ovarian cysts, endometriomas >4 cm or with solid areas, fibroids warranting surgical intervention, endometrial cancer or other significant endometrial pathology, or simple ovarian cysts >5 cm), pregnancy or breastfeeding, migraine with aura, severe liver dysfunction, smokers if aged ≥35 years, and with a history of or risk factors for venous and/or arterial thrombosis. Treatment Participants were randomly assigned (3:1) to receive either DSG/EE 150/20 μg or matching placebo and stratified by primary or secondary dysmenorrhea. Treatment was administered orally once daily for 24–80 consecutive days, each treatment followed by a 4-day TFI. Participants initially assigned to placebo were switched to active DSG/EE after completing 84 tablets during the DBTP (placebo-DSG/EE group). Patients were informed of withdrawal bleeding during a TFI, and irregular bleeding may occur with extended use. Scheduling or postponing TFI was based solely on patient discretion within the allowable minimum (24 days) and maximum (80 days) durations of continuous use. Endpoints Primary endpoint: change from baseline through day 84 in TDS. TDS ranged from 0 to 6 and consisted of a pain score and a drug score and was calculated as the sum of pain and drug scores on a scale from 0 to 6, with higher scores indicating severe dysmenorrhea (13). Key secondary endpoint: number of days with dysmenorrheic pain of at least mild intensity, measured by the menstrual pain score through day 84 and end of treatment (EOT) (14). Other secondary efficacy endpoints: patient-reported outcomes, such as the patient global impression of change (PGI-C) score (15) at day 85; treatment satisfaction as assessed by treatment satisfaction questionnaire for medication (TSQM-9) (16) at day 85 and EOT; occurrence of vaginal bleeding and use of analgesics through day 84 and EOT. Changes from baseline to day 85 in health-related QoL, as measured by the Short Form Health Survey version 2.0 (SF-36v2) physical component summary (PCS) (17, 18), mental component summary (MCS) scores (18, 19, 20), and individual health domains. Safety and treatment-emergent abnormalities in clinical laboratory assessments, vital signs, and physical examination were also assessed. These scales were selected to ensure clinical relevancy for Japanese and international audience and aid regulatory decision-making. Statistical analysis For the primary endpoint, sample size was calculated using assumptions based on a previous trial (21), which had a mean change after an 84-day treatment cycle from baseline in TDS of −3.1 for treatment and −0.9 for placebo. With a significance level of 0.05, 80% power, and a 3:1 randomization ratio, 27 participants (treatment group: 20; placebo: 7) were sufficient to detect a significant difference. For safety evaluation of 100 participants on DSG/EE treatment for 1 year and assuming a 40% dropout rate, approximately 168 participants were planned for active treatment group and 56 for placebo. Enrollment concluded after 211 participants were randomly assigned because of a lower-than-expected dropout rate. Continuous variables were summarized using mean and standard deviation (SD), and categorical variables as counts and percentages. The primary analysis was conducted in the full analysis set (FAS)—all randomly assigned participants who received ≥1 dose of the study treatment. Change from baseline in TDS through day 84 was evaluated using a mixed-model repeated-measures analysis for treatment group, dysmenorrhea type, TDS analysis visit, interaction between treatment and visit, and baseline TDS as a covariate. Results are presented as mean with standard errors (SE) or mean with SD, 95% confidence intervals (CIs), and P-values. The key secondary endpoint was analyzed using analysis of variance (ANOVA), with treatment group and type of dysmenorrhea as factors, applied to both observed and imputed data in FAS and active treatment DSG/EE analysis set (all participants from the randomization set who received ≥1 dose of DSG/EE, excluding participants who were in the placebo group that discontinued before switch). Other secondary endpoints were analyzed using ANOVA with the same fixed effects. PGI-C responses between groups were compared using Fisher’s exact test with CIs estimated by the Miettinen–Nurminen method. The SF-36v2 physical and mental component scores were analyzed using analysis of covariance with baseline score as a covariate. The number of days with dysmenorrheic pain and vaginal bleeding and analgesic use are summarized by time windows of 84 days (maximum length of a treatment cycle). Safety was assessed in all randomized participants who received ≥1 dose (safety analysis set). Treatment-emergent adverse events (TEAEs) were defined as events occurring from the first dose through 28 days after the last dose. Statistical analyses were performed using SAS 9.4 (SAS Institute Inc., Cary, NC). Results Patient disposition Of the 285 participants screened, 74 failed screening, and the remaining 211 were randomly assigned to receive DSG/EE (n = 159) or placebo (n = 52) in the DBTP. In the DSG/EE group, 114 participants had primary dysmenorrhea and 45 had secondary dysmenorrhea. In the placebo group, 38 participants had primary dysmenorrhea and 14 had secondary dysmenorrhea. Overall, 155 and 50 participants continued into the OLTP from the DBTP study, and 132 and 46 participants from the DSG/EE and placebo groups completed the study, respectively. A total of 209 participants were included in the active treatment DSG/EE analysis set, with 159 and 50 in the DSG/EE and placebo-DSG/EE groups, respectively (Fig.1).Figure 1Patient disposition. AE = adverse event; DBTP = double-blind treatment period; DSG/EE = desogestrel/ethinylestradiol; OLTP = open-label treatment period. Active treatment period (highlighted in blue color). Patient disposition. AE = adverse event; DBTP = double-blind treatment period; DSG/EE = desogestrel/ethinylestradiol; OLTP = open-label treatment period. Active treatment period (highlighted in blue color). Demographics and clinical characteristics All participants were women from Japan. Overall, baseline characteristics were similar, including mean age (32.4 vs. 31.9 years), weight (55.17 vs. 56.85 kg), and body mass index (21.85 vs. 22.22 kg/m2) in the DSG/EE and placebo groups, respectively. The mean (SD) menarche age was 12.2 (1.49) years in the DSG/EE group and 12.5 (1.57) years in the placebo group. The menstrual characteristics without hormonal contraceptive use were also similar between the groups (Table 1).Table 1Demographics and clinical characteristics (DBTP; Full Analysis Set).CharacteristicsDSG/EE (n = 159)Placebo (n = 52)Total (N=211)Age, mean (SD), y32.4 (7.63)31.9 (7.41)32.3 (7.56)Weight, mean (SD), kg55.17 (8.72)56.85 (8.94)55.58 (8.78)Height, mean (SD), cm158.84 (5.19)159.84 (4.63)159.09 (5.06)Body mass index, mean (SD), kg/m221.85 (3.18)22.22 (3.20)21.94 (3.18)Alcohol usage, n (%) Never19 (11.9)7 (13.5)26 (12.3) Current134 (84.3)40 (76.9)174 (82.5) Former6 (3.8)5 (9.6)11 (5.2)Tobacco usage, n (%) Never132 (83.0)43 (82.7)175 (82.9) Current6 (3.8)3 (5.8)9 (4.3) Former21 (13.2)6 (11.5)27 (12.8)Illicit drug use, n (%) No159 (100.0)52 (100.0)211 (100.0)Age of menarche (y)12.2 (1.49)12.5 (1.57)12.3 (1.51)Type of dysmenorrhea, n (%) Primary114 (71.7)38 (73.1)152 (72.0) Secondary45 (28.3)14 (26.9)59 (28.0)Typical cycle duration, mean (SD), d28.6 (2.63)28.7 (2.49)28.6 (2.59)Usual duration of flow, mean (SD), d5.9 (1.22)6.0 (1.00)5.9 (1.17)Usual volume of flow, n (%) Low5 (3.1)0 (0.0)5 (2.4) Moderate66 (41.5)16 (30.8)82 (38.9) Heavy88 (55.3)36 (69.2)124 (58.8)Presence of clots during flow, n (%) Yes135 (84.9)41 (78.8)176 (83.4) No24 (15.1)11 (21.2)35 (16.6)DSG/EE = desogestrel/ethinylestradiol. Table 1Demographics and clinical characteristics (DBTP; Full Analysis Set).CharacteristicsDSG/EE (n = 159)Placebo (n = 52)Total (N=211)Age, mean (SD), y32.4 (7.63)31.9 (7.41)32.3 (7.56)Weight, mean (SD), kg55.17 (8.72)56.85 (8.94)55.58 (8.78)Height, mean (SD), cm158.84 (5.19)159.84 (4.63)159.09 (5.06)Body mass index, mean (SD), kg/m221.85 (3.18)22.22 (3.20)21.94 (3.18)Alcohol usage, n (%) Never19 (11.9)7 (13.5)26 (12.3) Current134 (84.3)40 (76.9)174 (82.5) Former6 (3.8)5 (9.6)11 (5.2)Tobacco usage, n (%) Never132 (83.0)43 (82.7)175 (82.9) Current6 (3.8)3 (5.8)9 (4.3) Former21 (13.2)6 (11.5)27 (12.8)Illicit drug use, n (%) No159 (100.0)52 (100.0)211 (100.0)Age of menarche (y)12.2 (1.49)12.5 (1.57)12.3 (1.51)Type of dysmenorrhea, n (%) Primary114 (71.7)38 (73.1)152 (72.0) Secondary45 (28.3)14 (26.9)59 (28.0)Typical cycle duration, mean (SD), d28.6 (2.63)28.7 (2.49)28.6 (2.59)Usual duration of flow, mean (SD), d5.9 (1.22)6.0 (1.00)5.9 (1.17)Usual volume of flow, n (%) Low5 (3.1)0 (0.0)5 (2.4) Moderate66 (41.5)16 (30.8)82 (38.9) Heavy88 (55.3)36 (69.2)124 (58.8)Presence of clots during flow, n (%) Yes135 (84.9)41 (78.8)176 (83.4) No24 (15.1)11 (21.2)35 (16.6)DSG/EE = desogestrel/ethinylestradiol. Demographics and clinical characteristics (DBTP; Full Analysis Set). DSG/EE = desogestrel/ethinylestradiol. Primary efficacy endpoint The primary endpoint was met. A significant reduction in TDS from baseline through day 84 was observed in the DSG/EE group compared with placebo (mean: −2.50 vs. −0.84; treatment difference [95% CI]: −1.67 [−2.08, −1.26]; P<.001 (Table 2). In the primary dysmenorrhea subgroup, DSG/EE led to a significantly greater reduction from baseline through day 84 in TDS (mean change: −2.72) compared with placebo (−1.18), with a treatment difference (95% CI) of −1.54 (−2.03, −1.05); P<.001. Similarly, in the secondary dysmenorrhea subgroup, DSG/EE demonstrated a significantly greater reduction in TDS (mean change: −2.38) vs. placebo (−0.39), with a treatment difference (95% CI) of −1.99 (−2.77, −1.21); P<.001.Table 2Overall mean change from baseline in TDS and number of days with dysmenorrheic pain through day 84aOverall mean change from baseline in TDSTreatment differenceTreatment GroupnLSM (SE)95% CILSM (SE)95% CIP valueDSG/EE158b−2.50 (0.11)(−2.73, −2.28)−1.67 (0.21)(−2.08, −1.26)<.001Placebo52−0.84 (0.19)(−1.21; −0.47)Number of days with dysmenorrheic paincDSG/EE (n = 150)Placebo (n = 49)Menstrual pain score of at least mild intensityNumber of participants, n (%)144 (96.0)49 (100.0)Number of days, LSM (SE)12.9 (0.99)12.1 (1.65) Difference (DSG/EE vs placebo), LSM (95% CI)0.8 (−2.8; 4.4)Menstrual pain score of at least moderate intensityNumber of participants, n (%)126 (84.0)48 (98.0)Number of days, LSM (SE)4.8 (0.43)6.5 (0.72) Difference (DSG/EE vs placebo), LSM (95% CI)−1.7 (−3.3; −0.1)Menstrual pain score of severe intensityNumber of participants, n (%)35 (23.3)20 (40.8)Number of days, LSM (SE)0.8 (0.17)1.1 (0.29) Difference (DSG/EE vs placebo), LSM (95% CI)−0.3 (−0.9; 0.3)CI = confidence interval; DSG/EE = desogestrel/ethinylestradiol; LSM = lease squares mean; SE = standard error; TDS = total dysmenorrhea score.aOverall mean change from baseline is reported in full analysis set (FAS) and number of days with dysmenorrheic pain is imputed in completers.bOne patient in the DSG/EE group discontinued before study day 29.c9 (5.7%) participants in the DSG/EE group and 3 (5.8%) participants in the placebo group were excluded because of early discontinuation or ≥3 consecutive missing diary entries. Table 2Overall mean change from baseline in TDS and number of days with dysmenorrheic pain through day 84aOverall mean change from baseline in TDSTreatment differenceTreatment GroupnLSM (SE)95% CILSM (SE)95% CIP valueDSG/EE158b−2.50 (0.11)(−2.73, −2.28)−1.67 (0.21)(−2.08, −1.26)<.001Placebo52−0.84 (0.19)(−1.21; −0.47)Number of days with dysmenorrheic paincDSG/EE (n = 150)Placebo (n = 49)Menstrual pain score of at least mild intensityNumber of participants, n (%)144 (96.0)49 (100.0)Number of days, LSM (SE)12.9 (0.99)12.1 (1.65) Difference (DSG/EE vs placebo), LSM (95% CI)0.8 (−2.8; 4.4)Menstrual pain score of at least moderate intensityNumber of participants, n (%)126 (84.0)48 (98.0)Number of days, LSM (SE)4.8 (0.43)6.5 (0.72) Difference (DSG/EE vs placebo), LSM (95% CI)−1.7 (−3.3; −0.1)Menstrual pain score of severe intensityNumber of participants, n (%)35 (23.3)20 (40.8)Number of days, LSM (SE)0.8 (0.17)1.1 (0.29) Difference (DSG/EE vs placebo), LSM (95% CI)−0.3 (−0.9; 0.3)CI = confidence interval; DSG/EE = desogestrel/ethinylestradiol; LSM = lease squares mean; SE = standard error; TDS = total dysmenorrhea score.aOverall mean change from baseline is reported in full analysis set (FAS) and number of days with dysmenorrheic pain is imputed in completers.bOne patient in the DSG/EE group discontinued before study day 29.c9 (5.7%) participants in the DSG/EE group and 3 (5.8%) participants in the placebo group were excluded because of early discontinuation or ≥3 consecutive missing diary entries. Overall mean change from baseline in TDS and number of days with dysmenorrheic pain through day 84a CI = confidence interval; DSG/EE = desogestrel/ethinylestradiol; LSM = lease squares mean; SE = standard error; TDS = total dysmenorrhea score. Overall mean change from baseline is reported in full analysis set (FAS) and number of days with dysmenorrheic pain is imputed in completers. One patient in the DSG/EE group discontinued before study day 29. 9 (5.7%) participants in the DSG/EE group and 3 (5.8%) participants in the placebo group were excluded because of early discontinuation or ≥3 consecutive missing diary entries. Key secondary efficacy endpoint Number of days with dysmenorrheic pain Double-blind treatment period (DBTP) The mean (SE) number of days with dysmenorrheic pain of at least mild pain was 12.9 (0.99) in the DSG/EE group and 12.1 (1.65) in the placebo group, with a treatment difference (95% CI) of 0.8 days (−2.8, 4.4; Table 2). For at least moderate pain, the mean (SE) number of days was 4.8 (0.43) for DSG/EE group vs. 6.5 (0.72) days for placebo group, with a treatment difference (95% CI) of −1.7 days (−3.3, −0.1). For severe pain, the mean (SE) number of days was 0.8 (0.17) for DSG/EE group vs. 1.1 (0.29) days for placebo group, with a treatment difference (95% CI) of −0.3 days (−0.9, 0.3). Active treatment period (ATP) The mean number of days with dysmenorrheic pain of at least mild intensity decreased with the time of treatment for the DSG/EE and placebo-DSG/EE groups. For the mean number of days with at least moderate dysmenorrheic pain, a similar degree of reduction was observed in both groups. However, minimal changes were observed in mean number of days for the severe dysmenorrheic pain. A decreasing trend was generally observed in the proportion of participants experiencing at least mild and moderate dysmenorrheic pain in both groups (Supplemental Table 1, available online). Other secondary efficacy endpoints PGI-C score at day 85 At day 85, >80% of the participants in the DSG/EE group reported improvement (much better: 39.6%; a little better: 40.9%) in menstrual pain severity compared with <30% in the placebo group (much better: 3.8%; a little better: 25.0%). In the DSG/EE group, 9.4% of participants reported no change and 7.6% reported worsening, whereas in the placebo group, 65.4% reported no change and 1.9% reported worsening of menstrual pain (Supplemental Table 2). TSQM-9 Score at day 85 The DSG/EE group showed considerably higher mean (SE) global satisfaction (63.69 [1.73] vs. 36.62 [2.85]) and effectiveness scores (62.86 [1.58] vs. 35.5 [2.60]) compared with placebo, with mean differences (95% CI) of 27.06 (20.82, 33.30) and 27.36 (21.66, 33.06), respectively. Convenience scores were similar between the groups (72.96 [1.37] vs. 67.31 [2.26]), with mean difference (95% CI) of 5.65 (0.70, 10.59; Supplemental Table 3). Vaginal bleeding Double-blind treatment period Overall, 150 and 49 participants in the DSG/EE and placebo groups, respectively, were included in this analysis through day 84. The mean (SE) number of bleeding and/or spotting days was 24.3 (1.13) days in the DSG/EE group compared with 17.5 (1.87) days in the placebo group, with treatment difference (95% CI) of 6.9 days (2.7, 11.0). The mean (SE) length of vaginal bleeding and/or spotting episodes was 6.19 (0.30) days in the DSG/EE group and 4.82 (0.50) days in the placebo group, with treatment difference (95% CI) of 1.37 days (0.27; 2.46). Active treatment period A reduction in the mean number of vaginal bleeding and/or spotting days and the average length of vaginal bleeding and/or spotting episodes was observed in the last 84 days up to EOT for both the groups (Supplemental Table 4). Analgesic use Double-blind treatment period Overall, 150 and 49 participants in the DSG/EE and placebo groups, respectively, were included in this analysis through day 84. The mean (SE) number of days of analgesic use was 8.7 (0.85) days in the DSG/EE group and 8.4 (1.41) days in the placebo group, resulting in a treatment difference (95% CI) of 0.2 days (−2.9, 3.3). In the use of analgesics specifically to relieve menstrual pain, the mean (SE) was 4.5 (0.42) days for DSG/EE and 6.1 (0.70) days for placebo, with a treatment difference (95% CI) of −1.7 days (−3.2, −0.1). Active treatment period The number of days of analgesic use remained similar through EOT in both groups. The mean number of days of analgesic use to relieve menstrual pain reduced from 4.0 days through day 84 to 2.9 days in the last 84 days up to the EOT in the DSG/EE group. In the placebo-DSG/EE group, the mean reduction was from 3.1 days to 2.5 days, respectively (Supplemental Table 4). Change from baseline to day 85 in SF-36v2 At day 85, change from baseline mean (SE) PCS scores were higher in the DSG/EE group (3.13 [0.45]) compared with the placebo group (0.87 [0.73]), yielding a treatment difference (95% CI) of 2.26 (0.66, 3.85). Additionally, change from baseline mean (SE) MCS scores were lower in the DSG/EE group (1.04 [0.76]) compared with the placebo group (1.34 [1.25]), yielding a treatment difference (95% CI) of −0.30 (−3.04, 2.44). Of the eight subdomains of Health Status domain, participants in the DSG/EE group showed greater improvements in the (3.22 [0.51] vs. 0.55 [0.85]) and bodily pain (5.80 [0.81] vs. 0.90 [1.32]) domains compared with placebo, with treatment differences (mean [95% CI]) of 2.67 [0.81, 4.53] and 4.90 [1.99, 7.81], respectively. Changes were nonsignificant in the other subdomains of SF-36v2 (Supplemental Table 5). Safety Double-blind treatment period Overall, 126 (79.2%) participants in the DSG/EE and 27 (51.9%) participants in the placebo groups reported ≥1 adverse event (AE). TEAEs occurred in 121 (76.1%) participants receiving DSG/EE and 26 (50.0%) participants receiving placebo. TEAEs related to the study treatment were reported in 84 (52.8%) participants in the DSG/EE group and 9 (17.3%) in the placebo group (Table 3). The most frequently reported TEAEs were intermenstrual bleeding (69 participants; 32.7%), nasopharyngitis (30 participants; 14.2%), and nausea (14 participants; 6.6%; Supplemental Table 6). No severe or serious TEAEs, TEAEs of special interest (venous thromboembolic event, arterial thromboembolic event, or potential Hy’s Law case), or deaths were reported in either group during the DBTP. TEAEs leading to study treatment discontinuation occurred in 1 (0.9%) participant in each group (Table 3). In the DSG/EE group, the participant discontinued because of nausea and neck pain, whereas in the placebo group, the participant discontinued because of hypertension. One participant in both groups reported a TEAE of hypertension (in the DSG/EE group, this was reported as mild and unrelated to the study treatment and in the placebo group, was reported as moderate and unrelated).Table 3Overview of AEs during DBTP (safety analysis set) and ATP (active treatment DSG/EE analysis set)DBTPATPDSG/EE (n = 159)Placebo (n = 52)Total (N = 211)DSG/EE (n = 159)Placebo-DSG/EE (n = 50)Total (N = 209)AEs, n (%)126 (79.2)27 (51.9)153 (72.5)148 (93.1)46 (92.0)194 (92.8)TEAEs, n (%)121 (76.1)26 (50.0)147 (69.7)145 (91.2)39 (78.0)184 (88.0)Serious TEAEs, n (%)0 (0.0)0 (0.0)0 (0.0)3 (1.9)1 (2.0)4 (1.9)Severe TEAEs, n (%)0 (0.0)0 (0.0)0 (0.0)2 (1.3)1 (2.0)3 (1.4)TEAEs of special interest, n (%)0 (0.0)0 (0.0)0 (0.0)1 (0.6)1 (2.0)2 (1.0)Drug-related TEAEs, n (%)84 (52.8)9 (17.3)93 (44.1)108 (67.9)24 (48.0)132 (63.2)Serious drug-related TEAEs, n (%)0 (0.0)0 (0.0)0 (0.0)1 (0.6)1 (2.0)2 (1.0)Severe drug-related TEAEs, n (%)0 (0.0)0 (0.0)0 (0.0)0 (0.0)1 (2.0)1 (0.5)TEAEs leading to study treatment discontinuation, n (%)1 (0.6)1 (1.9)2 (0.9)10 (6.3)4 (8.0)14 (6.7)Serious TEAEs leading to discontinuation of study treatment, n (%)0 (0.0)0 (0.0)0 (0.0)2 (1.3)1 (2.0)3 (1.4)TEAEs of special interest leading to discontinuation of study treatment, n (%)0 (0.0)0 (0.0)0 (0.0)1 (0.6)1 (2.0)2 (1.0)TEAEs leading to death, n (%)0 (0.0)0 (0.0)0 (0.0)0 (0.0)0 (0.0)0 (0.0)Drug-related TEAEs leading to death, n (%)0 (0.0)0 (0.0)0 (0.0)0 (0.0)0 (0.0)0 (0.0)AE = adverse event; ATP = active treatment period; DBTP = double-blind treatment period; DSG/EE, desogestrel/ethinylestradiol; TEAE = treatment-emergent adverse event. Table 3Overview of AEs during DBTP (safety analysis set) and ATP (active treatment DSG/EE analysis set)DBTPATPDSG/EE (n = 159)Placebo (n = 52)Total (N = 211)DSG/EE (n = 159)Placebo-DSG/EE (n = 50)Total (N = 209)AEs, n (%)126 (79.2)27 (51.9)153 (72.5)148 (93.1)46 (92.0)194 (92.8)TEAEs, n (%)121 (76.1)26 (50.0)147 (69.7)145 (91.2)39 (78.0)184 (88.0)Serious TEAEs, n (%)0 (0.0)0 (0.0)0 (0.0)3 (1.9)1 (2.0)4 (1.9)Severe TEAEs, n (%)0 (0.0)0 (0.0)0 (0.0)2 (1.3)1 (2.0)3 (1.4)TEAEs of special interest, n (%)0 (0.0)0 (0.0)0 (0.0)1 (0.6)1 (2.0)2 (1.0)Drug-related TEAEs, n (%)84 (52.8)9 (17.3)93 (44.1)108 (67.9)24 (48.0)132 (63.2)Serious drug-related TEAEs, n (%)0 (0.0)0 (0.0)0 (0.0)1 (0.6)1 (2.0)2 (1.0)Severe drug-related TEAEs, n (%)0 (0.0)0 (0.0)0 (0.0)0 (0.0)1 (2.0)1 (0.5)TEAEs leading to study treatment discontinuation, n (%)1 (0.6)1 (1.9)2 (0.9)10 (6.3)4 (8.0)14 (6.7)Serious TEAEs leading to discontinuation of study treatment, n (%)0 (0.0)0 (0.0)0 (0.0)2 (1.3)1 (2.0)3 (1.4)TEAEs of special interest leading to discontinuation of study treatment, n (%)0 (0.0)0 (0.0)0 (0.0)1 (0.6)1 (2.0)2 (1.0)TEAEs leading to death, n (%)0 (0.0)0 (0.0)0 (0.0)0 (0.0)0 (0.0)0 (0.0)Drug-related TEAEs leading to death, n (%)0 (0.0)0 (0.0)0 (0.0)0 (0.0)0 (0.0)0 (0.0)AE = adverse event; ATP = active treatment period; DBTP = double-blind treatment period; DSG/EE, desogestrel/ethinylestradiol; TEAE = treatment-emergent adverse event. Overview of AEs during DBTP (safety analysis set) and ATP (active treatment DSG/EE analysis set) AE = adverse event; ATP = active treatment period; DBTP = double-blind treatment period; DSG/EE, desogestrel/ethinylestradiol; TEAE = treatment-emergent adverse event. There were no clinically significant changes in laboratory investigations or trends in vital signs during DBTP. In addition, TEAEs related to breast disorders, such as breast discomfort (3.8%), swelling (0.6%), and tenderness (0.6%) were reported in the DSG/EE group. Active treatment period TEAEs reported in the ATP are presented in Table 3. Most TEAEs were of mild severity (121 participants; 57.9%), followed by moderate (60 participants; 28.7%), and severe (3 participants; 1.4%) events. The most frequently reported TEAEs were intermenstrual bleeding (107 participants; 51.2%; reported under the following terms: intermenstrual bleeding, uterine hemorrhage, abnormal uterine bleeding, and heavy menstrual bleeding: 107, 4, 2, and two participants, respectively), nasopharyngitis (57 participants; 27.3%) and nausea (15 participants; 7.2%; Supplemental Table 6). Overall, 4 (1.9%) participants reported ≥1 serious TEAE; 3 (1.9%) in the DSG/EE group and 1 (2.0%) in the placebo-DSG/EE group. Of these, two reported serious TEAEs that were considered related to study treatment: 1 participant in the DSG/EE group experienced pulmonary embolism and deep vein thrombosis (DVT), and one participant in the placebo-DSG/EE group experienced DVT after switching from placebo to DSG/EE, who had concomitant COVID-19 infection. All three drug-related serious TEAEs were reported as recovered/resolved and considered as adverse events of special interest. No deaths were reported in the ATP. One clinically significant hematologic TEAE, iron deficiency anemia, was reported in 1 participant (0.6%) in the DSG/EE group, which was considered mild, nonserious, and possibly related to study treatment. Clinically significant liver function abnormalities, reported as nonserious TEAEs, were observed only in the DSG/EE group, with a total of 8 events in 6 participants. These events were considered mild to moderate and related to study treatment in 5 of the 6 participants. No drug-induced symptomatic hepatocellular injuries were reported. Urinalysis abnormalities included one clinically significant TEAE, hematuria, which was considered mild, nonserious, and unrelated to the study treatment in the DSG/EE group (1 participant; 0.6%). Clinically significant TEAEs related to vital signs and body weight included hypertension in 3 participants (all mild; 1 considered as study treatment-related) and increased weight in 3 participants (1.9%; 2 considered mild and unrelated to study treatment; 1 considered moderate and drug-related) in the DSG/EE group. Additionally, TEAEs related to breast disorders included fibroadenoma (1.0%), breast discomfort (3.8%), breast pain (1.0%), breast swelling (0.5%), and breast tenderness (0.5%). Discussion This study aimed to bring user-driven TFI timing to dysmenorrhea patients in Japan, demonstrated that DSG/EE significantly reduced mean TDS from baseline through day 84, and improved QoL compared with placebo. The study retained 178 out of the original 211 participants through the end of ATP and experienced 3 serious TEAEs, demonstrating the tolerability of DSG/EE. The primary efficacy endpoint demonstrated a statistically significant reduction in TDS from baseline through day 84 with DSG/EE compared with placebo (mean change: −2.50 vs. −0.84). Similar reductions in TDS were noted in both primary (mean: −2.72) and secondary dysmenorrhea subgroups (mean: −2.38). LEPs’ efficacy in reducing TDS scores was also previously documented in a Japanese randomized trial (21). The participants in the DSG/EE group had lower number of days with at least moderate or severe dysmenorrheic pain compared with placebo during DBTP. This finding aligns with previous research (7) and carries clinical significance as pain intensity and duration are closely associated with impaired QoL (22). In our study, DSG/EE in addition reduced analgesic use for menstrual pain relief compared with placebo, demonstrating reduced need for symptomatic relief, consistent with a previous study using a flexible extended regimen (7). Although, DSG/EE was associated with a higher number of bleeding and/or spotting days during the first 84 days, the mean number and average length of vaginal bleeding and/or spotting episodes was reduced through EOT, consistent with evidence that extended estrogen/progesterone regimens decrease breakthrough bleeding over time compared with cyclic regimens (23, 24). The PGI-C results demonstrated marked improvement in dysmenorrheic symptoms in the DSG/EE group, with >80% reporting improvement during DBTP. This finding was further corroborated by higher TSQM-9 scores in effectiveness and global satisfaction domains, consistent with previous findings on patient satisfaction with flexible regimens (7). Dysmenorrhea substantially affects physical, emotional, and social well-being (25). In this study, DSG/EE improved SF-36v2 scores, significantly in the SF-36v2 PCS, bodily pain, and role-physical domains, consistent with earlier studies on extended LEP regimens in Japanese patients (8, 26). In the DBTP, DSG/EE was associated with a higher incidence of TEAEs compared with placebo, most notably intermenstrual bleeding (32.7%), nasopharyngitis (14.2%), and nausea (6.6%). These were also the most common TEAEs in the ATP, predominantly mild to moderate in severity and consistent with the known DSG/EE safety profile (27). All bleeding events were considered mild except for 1 event (considered moderate in severity) and all were recovered/resolved. Overall, treatment satisfaction rates were high despite the incidence of breakthrough bleeding during treatment; there were only 3 participants who discontinued the study because of bleeding events. Thromboembolic events are a known and well-characterized risk of LEP pharmacological treatments containing EE (28). Two participants reported venous thromboembolism during the ATP. This safety profile is consistent with other LEP products and with the OCs drug class. Importantly, no new or unexpected safety signals emerged, supporting the safety of DSG/EE when used in a flexible extended regimen. Conclusion In conclusion, our findings demonstrated that the new user-driven flexible extended regimen of DSG/EE 150/20 was an effective and well-tolerated treatment for both primary and secondary dysmenorrhea. This regimen offers a patient-centered approach and introduces a new LEP treatment option for dysmenorrhea, which caters to daily activities and lifestyle of individuals with this condition. Declaration of Interests K.K. has received consulting fees from Organon, Mochida Pharmaceutical, Aska Pharmaceutical, Bayer, Tsumura Corp, Fuji Pharma, and MSD; honoraria for lectures, presentations, manuscript writing, and educational events from Organon, Mochida Pharmaceutical, Aska Pharmaceutical, Bayer, Tsumura Corp, Fuji Pharma, and MSD; and advisory board fees from Organon and also holds leadership positions in several academic and professional organizations. D.C., M.G., D.G., and T.Y. are current or former employees of Organon and may hold company shares. M.M. has received consulting fees from Organon and Nobelpharma; honoraria for lectures, presentations, manuscript writing, and educational events from Nippon Seiyaku, Mochida Pharmaceutical, Aska Pharmaceutical, Fuji Pharma, Torii Pharmaceutical, and Bayer; and advisory board fees from Organon and holds leadership positions in several academic and professional organizations.